Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The group hypothesized that teclistamab would have the same effect: its mechanism of action should stimulate "CD3-positive T-cell activation and the subsequent destruction of target cells," in ...

Mustang Bio makes the NASDAQ top percentage gainers list on FDA news, currently trading at $3.56. up $2.37, gaining 199% on volume of over 152 Million shares as of this report. The stock has a day's ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such ... activation in the periphery and do so only in the presence of Nectin-4 positive tumor cells, ...

A biopsy sample of the lesion showed an infiltrate of atypical T cells that were positive for CD2 and CD3 but negative for CD4, CD8, CD7, CD56, ALK, Epstein–Barr virus–encoded RNA (EBER ...

ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues.

The group hypothesized that teclistamab would have the same effect: its mechanism of action should stimulate "CD3-positive T-cell activation and the subsequent destruction of target cells," in ...

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.

Unlike other approaches that restrict activity to acidic tumor environments or rely on activated T-cells, APVO455 is designed to avoid binding to or triggering T-cell activation in the periphery and ...